Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-25-230511

Options or other derivatives

  • Chief Executive Officer acquired 49,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Kulkarni Samarth Chief Executive Officer 2025-10-03 Grant or award · Stock Option (Right to Buy) +49,500 49,500 D
Loading xslF345X05/ownership.xml…